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normal lung V5, V10, V20, mean lung dose (MLD) and other organs at risk (OARs) doses were evaluated. 
Total number of monitor units (MUs), beam‐on time, and patient‐specific quality assurance (QA) results 
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Results: The mean isocenter to tumor distance was 6.7 ± 2.3 cm. The mean combined PTV was 44.0 ± 
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single‐isocenter plan compared to a two‐isocenter plan. The single‐isocenter/two‐lesions VMAT lung 
SBRT QA plans demonstrated an accurate dose delivery of 98.1 ± 3.2% for clinical gamma passing rate of 
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Conclusion: The SBRT treatment of two peripherally located lung lesions with a centrally placed 
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Abstract
Purpose/objectives: To evaluate the plan quality and treatment delivery efficiency
of single‐isocenter/two‐lesions volumetric modulated arc therapy (VMAT) lung
stereotactic body radiation therapy (SBRT).
Materials/methods: Eight consecutive patients with two peripherally located early
stage nonsmall‐cell‐lung cancer (NSCLC) lung lesions underwent single‐isocenter
highly conformal noncoplanar VMAT SBRT treatment in our institution. A single‐iso-
center was placed between the two lesions. Doses were 54 or 50 Gy in 3 and 5
fractions respectively. Patients were treated every other day. Plans were calculated
in Eclipse with AcurosXB algorithm and normalized to at least 95% of the planning
target volume (PTV) receiving 100% of the prescribed dose. For comparison, two‐
isocenter plans (isocenter placed centrally in each target) were retrospectively cre-
ated. Conformity indices (CIs), heterogeneity index (HI), gradient index (GI), gradient
distance (GD), and D2cm were calculated. The normal lung V5, V10, V20, mean lung
dose (MLD) and other organs at risk (OARs) doses were evaluated. Total number of
monitor units (MUs), beam‐on time, and patient‐specific quality assurance (QA)
results were recorded.
Results: The mean isocenter to tumor distance was 6.7 ± 2.3 cm. The mean com-
bined PTV was 44.0 ± 23.4 cc. There was no clinically significant difference in CI,
HI, GD, GI, D2cm, and V20 including most of the OARs between single‐isocenter
and two‐isocenter lung SBRT plans, evaluated per RTOG guidelines. However, for
single‐isocenter plans as the distance between the lesions increased, the V5, V10,
and MLD increased, marginally. The total number of MUs and beam‐on time was
reduced by a factor of 1.5 for a single‐isocenter plan compared to a two‐isocenter
plan. The single‐isocenter/two‐lesions VMAT lung SBRT QA plans demonstrated an
accurate dose delivery of 98.1 ± 3.2% for clinical gamma passing rate of 3%/3 mm.
Conclusion: The SBRT treatment of two peripherally located lung lesions with a
centrally placed single‐isocenter was dosimetrically equivalent to two‐isocenter
plans. Faster treatment delivery for single‐isocenter treatment can improve patient
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compliance and reduce the amount of intrafraction motion errors for well‐suited
patients.
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1 | INTRODUCTION
For medically inoperable stage I/II nonsmall‐cell lung cancer (NSCLC)
patients, several Phase I/II trials have shown that the use of stereo-
tactic body radiation therapy (SBRT) treatment for solitary lung
lesions representing the primary tumor mass is safe, effective, and
has a high cure rate comparable to surgery.1–7 In these studies, med-
ically inoperable patients with early‐stage NSCLC who underwent
SBRT had 3‐yr primary tumor local control rates of up to 98% and a
low risk of treatment‐related toxicity.
In the setting of either multiple primary lung cancers or limited
metastatic lesions to the lungs (oligometastastic), SBRT presents a rel-
atively new treatment opportunity. Optimal treatment planning must
consider microscopic disease extension around the visible mass and
allow for tumor movement, primarily due to respiration. Multiple
metachronous or synchronous lung cancers are relatively common and
have been managed by SBRT.8 Based on Phase I/II trials of SBRT in
the management of oligometastastic lung lesions, for patients with
one to three tumors, up to five tumors (with curative intent) and more
than five tumors with palliative treatment have been reported.9,10
Rusthoven and colleagues treated 38 patients, 63 total tumors, with
lung SBRT of total dose of 48–60 Gy in 3 fractions. Actuarial local con-
trol rates at 1‐ and 2‐yr after SBRT was 100% and 96% respectively.10
SBRT to multiple lung lesions presents with technical challenges
and can be treated either sequentially with separate treatment plans
or synchronously to all lesions. However, the location and geometry of
synchronous plans can be challenging since minor inaccuracies of
patient setup can result in geometric misses. Attention must be paid to
overlapping doses to organs at risk (OARs) and respiratory control is
critical since different parts of the lung can move independently.
Sequential treatment plans for each individual tumor, using a multi‐iso-
centric technique requires relatively longer planning and treatment
delivery time. Safe and effective delivery of SBRT of lung requires pre-
cise, highly conformal treatment planning and delivery techniques.11–13
In the past decades, treatment techniques for lung SBRT included Lin-
ear accelerator‐based 3D‐conformal radiation therapy, intensity modu-
lated radiation therapy (IMRT), volumetric modulated arc therapy
(VMAT) (RapidArc,Varian Inc., Palo Alto, CA, USA), CyberKnife, and
helical Tomotherapy (Accuray Inc., Sunnyvale, CA, USA). However, as
the complexity of the technology has evolved, treatment has required
very high total monitor units (MU) and relatively long treatment times
to deliver a highly conformal plan and spare OARs.14–16
With the recent technological advances, VMAT may provide
highly conformal radiation dose delivery with faster delivery
times.17–20 The VMAT lung SBRT simultaneously optimizes gantry
speed, multileaf collimator (MLC) position and high dose‐rate (FFF,
flattening filter free mode) to provide highly conformal dose distribu-
tions to the planning target volume (PTV) while minimizing dose to
adjacent OARs. Reducing treatment time would improve patient
compliance which helps reduce error due to motion, and promote
more efficient clinic flow. For multiple brain metastases, recent stud-
ies have shown that single‐isocenter VMAT can provide highly con-
formal radiosurgical dose distributions, excellent plan quality and
safe and faster treatment delivery compared to conventional multi‐
isocenter technique.21–23 However, there is little literature in the
medical physics community on the treatment of multiple lung lesions
using single‐isocenter VMAT‐SBRT technique.
A few studies have examined the use of single‐isocenter SBRT for
multiple lung lesions. A study by Trager et al.24 discusses the use of a
technique that utilizes a single‐isocenter with distinct optimizations
for extracranial radiosurgery. Gulam et al.25 examined six patients and
found that the criteria set forth by Radiation Therapy Oncology Group
(RTOG) study 0915 protocol was met with regard to CI, but not some
other critical dosimetric parameters. A retrospective study in total ele-
ven patients by Quan et al.26 showed no difference in multiple dosi-
metric parameters between single‐isocenter VMAT plans (four single‐
isocenter VMAT plans were compared) and multi‐isocenter intensity‐
modulated SBRT to the lung. Still, the ability of a single‐isocenter
treatment to two or more lung lesions to deliver curative treatment
plans in adherence with RTOG 0915 dosimetric compliance criteria
has not been fully explored. In this report we present our recently
adopted treatment method utilizing single‐isocenter VMAT plan for
SBRT of two lung lesions evaluated per RTOG 0915. For complete-
ness, the original single‐isocenter lung SBRT plans and retrospectively
generated conventional two‐isocenter lung SBRT plans were com-
pared via their protocol compliance, plan quality, dose to critical struc-
tures, treatment delivery efficiency, and accuracy.
2 | MATERIALS AND METHODS
2.A | Patient setup and target delineation
A total of eight sequential patients were included in this retrospec-
tive study, all of whom had two peripherally located Stage I NSCLC
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lesions. The patients were immobilized using Body Pro‐Lok™ platform
(CIVCO system, Orange City, IA) in the supine position with their
arms above their head with abdominal compression, potentially
reducing diaphragmatic motion to less than or equal to 1.0 cm. Con-
ventional 3D CT scans and respiration‐correlated 4D CT scans were
acquired on a GE Lightspeed 16 slice CT scanner (General Electric
Medical Systems, Waukesha, WI) with 512 × 512 pixels at 2.5 mm
slice thickness in the axial cine mode. Varian's Real Time Position
Management Respiratory Gating System (version 1.7) was used for
collection of 4D CT data. All 10 phases of 4D CT slices and respira-
tory motion signal were transferred to an Advantage 4D Worksta-
tion (General Electric Medical Systems, San Francisco, CA), where
the maximum intensity projection (MIP) images were generated after
a phase binning of the 4D CT images. In addition to the MIP images,
the motion of both tumors was evaluated by an experienced physi-
cist to affirm synchronous tumor motion that was less than 1 cm.
The regular 3D CT scan and the MIP images were imported into the
Eclipse treatment planning system (TPS) (version 13.0, Varian Medi-
cal Systems, Palo Alto, CA) and coregistered for target contouring.
Gross tumor volumes (GTV) and internal tumor volumes (ITV) were
delineated on the 3D CT images with references to the MIP images.
Planning target volumes (PTV) were generated by adding non‐uni-
form 5–10 mm margins to the ITV to accommodate the patient
setup uncertainties based on tumor size, location and synchronous
tumor motion. The critical structures, such as bilateral lungs exclud-
ing the ITV (normal lung), spinal cord, ribs, heart, great vessels,
esophagus, and skin were delineated on the 3D CT images.
2.B | Treatment planning
2.B.1 | Clinical single‐isocenter VMAT Plan
Highly conformal, clinically optimal VMAT treatment plans were
generated using 3–4 non‐coplanar partial arcs (5–10°, couch kicks
were used for arcs) for the Truebeam linear accelerator (Varian,
Palo Alto, CA) with millennium MLC and a 6 MV‐FFF (1400 MU/
min) beam. A single‐isocenter was placed approximately between
the two lesions. As the isocenter location does not need to be
exactly in the middle of the lesions, an offset allowing for the gan-
try to rotate in a partial arc can be made. For those arcs, collimator
angles were chosen in such a way that the opening of the MLC
between tumors was minimized while the gantry rotates around
the patient. Additionally, jaw tracking was used to further minimize
the out of field leakage dose. The isocenter to tumors distance
was the maximum 3D‐linear distance from the single‐isocenter loca-
tion to the geometric center of the individual tumor/isocenter. This
distance was calculated in the TPS using the x‐, y‐, and z‐ primary
coordinates of the tumor centers. This distance was estimated to
evaluate the normal lung doses as a function of isocenter distance
from the targets. A dose of 54 or 50 Gy in 3 and 5 fractions was
prescribed to the PTV D95%. All clinical treatment plans were cal-
culated using the Eclipse TPS with Acuros‐XB (version 13.6.0, Var-
ian Medical Systems, Palo Alto, CA) algorithm on the 3D CT
images for heterogeneity corrections with a 2.0 × 2.0 × 2.0 mm3
dose calculation grid‐size. Dose to medium reporting mode was
selected. All clinical plans were inversely optimized using variation
of gantry rotation speed, dose rate and MLC positions. The gener-
alized normal tissue objective (NTO) parameters were used to con-
trol the gradients for single‐isocenter clinical plan. As recommended
by Varian, in our department, we used the following NTO parame-
ters for lung SBRT plans: NTO with high priority of 150 with dis-
tance to target border of 0.1 cm. Start dose of 100.0% and end
dose of 40% was used with a fall‐off factor of 0.5/mm. Moreover,
the ring structures of 5, 10, and 20 annulus from each lesion with
5 mm gaps were generated to enforce the high dose regions (typi-
cally enforcing maximum 120% hotspot inside each ITV) and mini-
mize the intermediate dose spillage. All the planning objectives
were per RTOG 0915 guidelines. The patients were treated every
other day per lung SBRT protocol.
2.B.2 | Two‐isocenter VMAT plan
For comparison, the SBRT treatment plans for all patients were ret-
rospectively replanned with a conventional two‐isocenter approach.
Individual isocenters were placed in the geometric center of each
tumor. For each target, the plans were generated using 3–4 non-
coplanar partial arcs, similar to single‐isocenter plan. Collimator rota-
tions and jaw tracking were applied. The plan for the first tumor
(PTV1) was first computed using same RTOG guidelines as described
before. The plan for PTV1 was then used as the base‐plan for gener-
ating the plan for the second tumor (PTV2) in order to allow full
scatter contributions from both plans. All the planning objectives
used were the same as the single‐isocenter plan including the NTO
parameters and ring structures. Dosimetric parameters for the target
coverage and the adjacent OARs, including normal lung, were evalu-
ated.
2.C | Plan evaluation
Each plan was evaluated for the target coverage and the dose to
OARs. For example, using the percentage prescribed isodose volume
and target size, the RTOG conformity index (CI) was calculated as
follows:27
RTOG CI ¼ Rx Isodose Volume
PTV volume
(1)
Ideally, CI = 1.0, implying a perfectly conformal plan. The RTOG
recommendation for the CI is <1.2 with 1.2–1.5 being acceptable
with minor deviations. In addition, the Paddick conformation number
(CN) was calculated by:28
Paddick CN ¼ ðTVPIVÞ
2
ðTV  PIVÞ (2)
where TVPIV is the target volume covered by the prescription iso-
dose volume, TV is the target volume and PIV is the prescription iso-
dose volume. CN = 1.0 would be ideal. The heterogeneity index (HI)
was determined by:
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HI ¼ D10%
D95%
(3)
where D10% is the dose to the hottest 10% of the PTV and D95%
is the dose to the 95% of the PTV coverage. The intermediate dose
spillage was evaluated by using, gradient index (GI), D2cm and gradi-
ent distance (GD). The GI was given by:
GI ¼ R50%
R100%
(4)
where R50% is the ratio of 50% prescription isodose volume to the
PTV and R100% is the ratio of 100% prescription isodose volume to
the PTV. Per RTOG, depending on the target size, a GI of 3.0–6.0 is
desirable. Similarly, D2cm is the maximum dose, in percent of dose
prescribed, at 2 cm from the PTV in any direction; and the GD, is
the average distance from 100% prescription dose to 50% of the
prescription dose. Although, RTOG only recommended normal lung,
V20 < 10% (10–15% was acceptable with minor deviations), we
have evaluated V5, V10, and mean lung dose (MLD) for normal lung
for all plans.
2.D | Dose to other OARs
In addition to the lung dose, all the clinical single‐isocenter plans
were evaluated for dose to spinal cord, heart, esophagus, tra-
chea, ribs, and skin per RTOG guidelines. The dose volume his-
togram parameters were compared between the single‐isocenter
and the two‐isocenter plans. The mean and standard deviation
values for each of the dose metrics were compared using paired
t tests for single‐isocenter vs two‐isocenter computed dosimetric
parameters for the OARs dose tolerances using an upper bound
of P < 0.05.
2.E | Delivery efficiency and accuracy
The dose delivery efficiency of each lung SBRT plan was evaluated
based on total number of MU and actual beam‐on time. For the
single‐isocenter plan, actual beam on time was recorded at the treat-
ment machine while delivering the VMAT‐SBRT QA plan. Delivery
accuracy of the VMAT‐SBRT QA plan was evaluated by physically
measuring the 2D dose distribution of each plan using an Octavius
phantom (PTW, Freiburg, Germany). All QA plans were delivered at
the machine the day before the patient's 1st treatment. The mea-
sured cumulative 2D dose plan was compared with the computed
dose distributions calculated on the Octavius QA phantom plan by
the TPS. Upon completion of delivered dose, data were analyzed
with Octavius MEPHYSTO Navigator (VeriSoft Patient Plan Verifica-
tion, Version 6.3, PTW) using the standard clinical gamma passing
rate criteria of 3%/3 mm maximum dose difference and distance‐to‐
agreement (DTA) with 10% threshold as well as point dose. Since
the two‐isocenter plans were not used for patient treatment, no
VMAT QA was done. The beam on time was estimated by using
dose rates of 1400 MU/min for these plans.
3 | RESULTS
3.A | Target coverage and normal lung dose
All patients were treated with a single‐isocenter VMAT plan in our
clinic, which utilized 2–4 noncoplanar partial arcs. The prescription
dose was 50–54 Gy in 3–5 fractions for at least 95% of the PTV
receiving 100% of the prescribed dose. The single‐isocenter to
tumors distance was calculated in the TPS using the x‐, y‐, and z‐ pri-
mary coordinates of the tumor centers, as described above. The
isocenter to tumor distance was approximately 3.7 to 9.6 cm (mean,
6.7 ± 2.3 cm). The mean combined PTV was 44.0 ± 23.4 cc (range,
20.5–91.8 cc). The DVHs for both single‐isocenter and two‐isocenter
treatment plans are shown in Fig. 1 for patient #8. In this case, both
planning approaches produced dosimetrically equivalent plans. How-
ever, the treatment delivery time for the single‐isocenter technique
is reduced by a factor of 1.5. That was just a reported treatment
delivery time, the actual patient setup and verification for the second
isocenter with two‐isocenter plan would take extra‐time, prolonging
the treatment delivery.
Figure 2 displays a sagittal view of both single‐isocenter and
two‐isocenter treatment plans for the same patient (#8). In this case,
the normal lung V5 and V10 were similar; V20 was slightly higher
with single‐isocenter plan compared to two‐isocenter plan. However,
both plans met the RTOG compliance criteria for the target coverage
(see Table 1), normal lung and the other OARs dose tolerances.
Detail of the plan comparison for target coverage including
tumor location and the tumors distance from the isocenter are
shown in Table 1.
All lung SBRT plans were acceptable per RTOG guidelines for
the high (CI, HI) and intermediate dose spillage (GI and D2cm). In
addition, similar results were shown for the Paddick CN between
the two plans. No clinically significant difference was observed in CI,
HI, GD, GI, and D2cm between single‐isocenter and two‐isocenter
lung SBRT plans evaluated per RTOG guidelines by the treating
physician. However, the GD values were slightly higher with single‐
isocenter plan of about 3–5 mm, especially for the larger tumor dis-
tance from the isocenter compared to two‐isocenter plan. Clinical
significance of higher GD values, compared to relatively faster deliv-
ery of single‐isocenter plan, may need to be explored.
The absolute differences between single‐isocenter and two‐iso-
center plans for normal lung V20, V10, V5, and MLD were listed in
the Table 2. All patients had V20 < 10–15% for both treatment
plans. A statistically insignificant difference (P = 0.09) was found for
the normal lung V20 between two plans. However, V10, V5, and
MLD increases slightly with single‐isocenter plan compared to two‐
isocenter plan, giving statistically significant differences (P = 0.03,
0.01 and 0.03 respectively). Statistically significant P‐values are high-
lighted in bold (see Table 2). Although, V10, V5, and MLD had
shown statistically significant differences, the absolute differences
were on the order of less than 0.8% for V20, 2.8% for V10 and
6.5% for V5) and less than 60 cGy for MLD, on average, therefore,
we do not expect the differences would be clinically significant.
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The ratios between single‐isocenter and two‐isocenter plans for
the V20, V10, and V5 as a function of isocenter to tumors distance
can be seen in Fig. 3. When the isocenter to tumor distance
increased, the low dose volume to the normal lung, such as V5 and
V10, was slightly increased. However, two of eight patients had
lower values of V20 with single‐isocenter plan.
3.B | Dose to other OARs
A comparison of other OARs dosimetric parameters for single‐iso-
center and two‐isocenter plans for all eight lung SBRT patients is
presented in Table 3. Critical organs such as spinal cord (Dmax, and
D0.35cc), heart (Dmax and D15cc), esophagus (Dmax and D5cc), trachea
(Dmax and D4cc), ribs (Dmax and D1cc), and skin (Dmax and D10cc) were
evaluated per SBRT protocol guidelines.
The average values of maximum doses to spinal cord, ribs, and
skin were similar (also see the average of the ratios in Table 3)
between the two planning methods. Although, the average values
of the absolute dose differences and ratios for heart, esophagus
and trachea were slightly higher with single‐isocenter plan, the
average absolute dose differences were up to 1–2 Gy. While eval-
uating those plans per SBRT protocol's guidelines, those values
met the protocol criteria, therefore, the differences were not
deemed clinically significant. Almost all P‐differences were
F I G . 1 . This shows the dose volume histogram comparison for the target coverage (for both PTV1 and PTV2). The ITVs (red) and a few OAR
such as total normal lung (light blue), heart (dark blue), ribs (green), and spinal cord (orange) are shown for patient #8. Prescription dose was
54 Gy in three fractions. The square symbols representing the single‐isocenter plan, and the triangle symbols representing the two‐isocenter
plan. Both plans were normalized to at least 95% of PTV received 100% of the prescribed dose. In this case, the isocenter to tumors distance
was about 4 cm; the dosimetrically equivalent plans were generated using single‐isocenter technique, as demonstrated, with similar target
coverage and dose to the OARs.
F I G . 2 . This is a comparison of isodose distributions in sagittal view for the same patient #8 generated via single‐isocenter and two‐
isocenter plans. In the right panel a single‐isocenter location is shown by the intersection of the cross‐hair; in the left panel two‐isocenter plan
sum is shown for the both targets (PTV1 and PTV2). Target volumes contoured include both ITVs (red, innermost) followed by PTVs (orange
and green, outermost). Higher isodose lines, such as 54 Gy (100%), 51.3 Gy (95%), 48.6 Gy (90%), 43.2 Gy (80%), exhibit sharp dose fall off for
the both plans, including 27.0 Gy (50%) isodose line (blue). In both plans, the hotspot, 120% isodose line (thick‐orange) was shown in the
middle of the ITV. Other OARs such as ribs and lung contours are shown. Purple color rings were contoured to calculate D2cm (%) for each
target.
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insignificant, except for dose to 15 cc of heart (P = 0.002) and
dose to 10 cc of ribs (P = 0.02). Both the single‐isocenter and
two‐isocenter plans were within clinically acceptable limits per
RTOG 0915.
3.C | Delivery efficiency and accuracy
For single‐isocenter plans, the mean values of total number of MUs
and beam on time were 6014 (4013 to 10,727) and 4.3 min (2.9 to
TAB L E 1 Comparison of plan evaluation parameters for single‐isocenter vs two‐isocenter treatment plans of all eight lung SBRT patients.
Lesion 1 (PTV1 plan) and Lesion 2 (PTV2 plan) and two‐isocenter (Two‐iso) plan sum.
Patient
no.
Plan type and
tumor location
Combined
PTV (cc)
RTOG
CI
Paddick
CN HI GI
D2cm
(%)
GD
(cm)
Isocenter to
tumors distance
(cm)
1 Lesion 1, LUL 5.0 1.08 0.75 1.16 6.6 47.9 0.90 5.2
Lesion 2, LLL 16.1 1.01 0.84 1.17 4.1 41.4 0.95
Two‐iso (plan sum) 21.1 1.05 0.81 1.18 4.8 47.6 0.97
Single‐isocenter 1.05 0.79 1.16 5.0 56.5 1.20
2 Lesion 1, LUL 30.7 1.01 0.83 1.11 4.2 57.3 1.21 9.5
Lesion 2, RUL 43.6 0.99 0.84 1.22 3.6 55.2 1.18
Two‐iso (plan sum) 74.3 1.02 0.80 1.23 4.2 60.2 1.24
Single‐isocenter 1.02 0.82 1.21 4.6 62.8 1.75
3 Lesion 1, LLL 16.2 1.05 0.76 1.17 4.8 50.8 1.05 9.6
Lesion 2, RUL 34.9 1.19 0.68 1.08 5.5 69.2 1.43
Two‐iso (plan sum) 51.1 1.26 0.70 1.26 5.4 76.3 1.49
Single‐isocenter 1.29 0.67 1.39 6.4 80.5 1.78
4 Lesion 1, LLL 8.6 1.03 0.80 1.17 4.8 43.2 0.87 4.6
Lesion 2, RUL 26.6 1.01 0.84 1.20 4.1 51.8 1.11
Two‐iso (plan sum) 35.2 1.07 0.76 1.22 4.9 55.9 1.21
Single‐isocenter 1.16 0.74 1.18 5.5 53.6 1.45
5 Lesion 1, LUL 80.9 0.99 0.83 1.15 3.3 56.1 1.34 8.4
Lesion 2, RLL 10.9 1.02 0.72 1.21 5.0 48.7 0.97
Two‐iso (plan sum) 91.8 1.01 0.81 1.17 3.9 57.6 1.38
Single‐isocenter 1.02 0.81 1.16 4.1 56.4 1.68
6 Lesion 1, Ant. LLL 19.6 1.04 0.77 1.16 4.3 49.3 1.02 4.8
Lesion 2, Post. LLL 7.7 1.20 0.63 1.20 6.7 44.8 1.00
Two‐iso (plan sum) 27.3 1.09 0.72 1.19 5.6 50.3 1.11
Single‐isocenter 1.03 0.76 1.17 5.3 48.7 1.38
7 Lesion 1, RUL 13.6 1.04 0.67 1.10 5.3 48.0 1.04 4.9
Lesion 2, LUL 17.2 1.02 0.78 1.05 4.5 48.6 1.03
Two‐iso (plan sum) 30.8 1.05 0.62 1.11 5.6 51.4 1.09
Single‐isocenter 1.04 0.70 1.16 5.2 48.6 1.43
8 Lesion 1, Post.
RUL
13.5 0.99 0.83 1.19 4.3 46.5 0.94 3.7
Lesion 2, Ant. RUL 8.0 1.00 0.80 1.18 5.1 45.4 0.90
Two‐iso (plan sum) 21.5 1.04 0.81 1.19 4.8 47.0 1.13
Single‐isocenter 1.03 0.81 1.19 5.1 48.9 1.23
TAB L E 2 Normal lung doses statistics between single‐isocenter and two‐isocenter plans for all eight lung SBRT patients. Data were presented
as mean ± standard deviation (range) and P‐values.
Plan type V20 (%) V10 (%) V5 (%) MLD (Gy)
Two‐isocenter 6.7 ± 2.7 (2.9 to 12.2) 18.2 ± 6.7 (7.2 to 29.9) 29.7 ± 10.4 (21.1 to 46.5) 5.4 ± 1.4 (3.3 to 8.2)
Single‐isocenter 7.5 ± 13.4 (3.2 to 13.5) 21.0 ± 8.9 (7.5 to 36.8) 36.1 ± 13.8 (18.2 to 61.7) 6.0 ± 1.8 (3.7 to 9.2)
P‐value 0.09 0.03 0.01 0.03
Statistically significant P‐values are highlighted in bold.
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7.7 min). For each clinical single‐isocenter plan, actual beam‐on time
was recorded at the treatment machine (to verify the calculated beam
on time) while delivering VMAT QA plan as mentioned earlier. For all
cases reported here, the maximum dose rate of 1400 MU/min for 6X‐
FFF beam was used. That (dose rate) was reviewed for each VMAT arc
for all patients under the MLC properties tab. In addition, maximum
dose rate of 1400 MU/min was visually observed (all the time) at the
Octavius VMAT QA delivery at Truebeam for all clinical single‐isocen-
ter/two‐lesion lung SBRT plans. This suggest that for these high dose
(high MUs) per fraction treatment the beam on time was dictated by
total number of MUs per arc (as expected) rather than gantry rotation
speed. Compared to two‐isocenter plans, the total number of MUs
and beam on time were reduced by a factor of 1.5. Furthermore, with
two‐isocenter plans, the actual patient setup and verification for the
second isocenter plan would take extra‐time, prolonging the treatment
delivery. In addition, lower total MUs could potentially deliver lower
leakage dose. The complete details regarding number of MUs, beam‐
on time, VMAT QA gamma pass rates, and the measured point dose
percent difference are found in Table 4. Since the isocenter location
for single‐isocenter was under the MLC, the maximum point dose was
measured at the middle of the targets where the maximum fluence
was delivered off axis to the two targets and compared to the com-
puted VMAT QA plan on Octavius phantom.
The Octavius VMAT QA pass rates for the single‐isocenter plan
was 98.1 ± 3.0%, on average, for 3%/3 mm clinical gamma pass rate
criteria and the point dose measurement was about within 1%, on
average, suggesting that an accurate delivery of the lung SBRT plan.
However, for patient #2, the gamma pass rates were around 92% for
3%/3 mm criteria. In this case, both tumors were relatively large, and
the tumors to isocenter distance was relatively large, around 9.5 cm.
In addition, the tumors were located in the bilateral lungs, therefore,
the MLCs have to travel a longer distance, providing suboptimal
VMAT QA pass rates; suggesting that exceeding 10 cm (isocenter to
tumors distance) may not provide clinically optimal plan with single‐
isocenter. While reanalyzing those data with a tighter distance‐to‐
agreement (3%/2 mm) criteria, the average value of gamma pass rate
was 95.8 ± 3.8% (ranged, 90.6 to 100%) that was within the depart-
mental SBRT VMAT QA pass rate criteria (>/=90.0% pass rates).
Since, the two‐isocenter plans were not used for actual patient's
treatment we did not run VMAT QA for those plans.
4 | DISCUSSION
In this study, we have presented our initial clinical experiences of a
fast, effective, and accurate treatment planning and delivery
F I G . 3 . Scatter plot: For all eight lung SBRT patients, the ratios of V5,
V10 and V20 of normal lung doses calculated by single‐isocenter and
two‐isocenter plans as a function of isocenter to tumors distance. For
the identical planning objectives, the single‐isocenter plan gave slightly
higher values of V5, V10, and V20 by a factors of 1.2, 1.1, and 1.1, on
average, respectively, compared to two‐isocenter plan. This suggests
that comparable dosimetric parameters can be obtained for the normal
lung. However, single‐isocenter plan would have considerably faster
treatment delivery by an almost a factor of 2, eliminating the setup and
verification time for the second isocenter plan.
TAB L E 3 Average values of absolute dose differences between single‐isocenter and two‐isocenter plans for the other major dose distribution
parameters of the OARs for all eight lung SBRT patients.
OARs Parameters Mean ± SD (Gy) Range (Gy) Ratioa P‐value
Spinal cord Dmax 0.5 ± 1.1 −0.9 to 2.9 1.05 ± 0.13 0.25
D0.35cc 0.5 ± 1.1 −0.7 to 2.7 1.03 ± 0.13 0.62
Heart Dmax 0.9 ± 3.0 −5.4 to 5.0 1.07 ± 0.14 0.42
D15cc 2.0 ± 1.2 0.0 to 3.9 1.15 ± 0.09 0.002
Esophagus Dmax 2.1 ± 3.9 −4.5 to 3.5 1.13 ± 0.23 0.18
D5cc 1.9 ± 3.3 −3.3 to 4.6 1.18 ± 0.31 0.15
Trachea Dmax 0.7 ± 1.8 −5.0 to 5.9 1.13 ± 0.27 0.55
D4cc −0.8 ± 1.8 −4.5 to 1.0 0.96 ± 0.27 0.27
Ribs Dmax 0.0 ± 3.9 −5.1 to 7.4 0.99 ± 0.08 0.98
D1cc −0.1 ± 2.2 −4.5 to 2.4 0.99 ± 0.07 0.91
Skin Dmax −0.6 ± 1.5 −3.9 to 0.6 0.97 ± 0.07 0.28
D10cc 1.2 ± 1.1 −0.4 to 2.8 1.11 ± 0.08 0.02
Absolute dose differences = single‐isocenter–two‐isocenter. The negative sign indicates that the results of the two‐isocenter plans were larger than
those of single‐isocenter plans. Statistically significant P‐values are highlighted in bold.
aSingle‐isocenter/two‐isocenter.
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technique using single‐isocenter VMAT plans for SBRT of two lung
lesions following RTOG 0915 protocol guidelines.12 Our single‐iso-
center VMAT plan for SBRT of two lung lesions uses 3–4 noncopla-
nar partial arcs with jaw tracking and patient specific collimator
angles to minimize leakage dose from leaves travelling in between
the tumors. Single‐isocenter VMAT‐SBRT plans were highly confor-
mal and achieved adequate target coverage (see Table 1 for CI, HI,
Paddick CN, GI, D2cm, and GD) compared to conventional two‐iso-
center plans. For all patients, the single‐isocenter plans met RTOG
guidelines including normal lung V20 and were similar compared to
two‐isocenter plans. However, when the isocenter to tumors distance
increased, the low dose volume to the normal lung, such as V5 and
V10, was slightly increased as shown in Fig. 3. In addition, the other
OARs such as spinal cord, heart, esophagus, trachea, ribs, and skin
dose tolerances were also within protocol. The single‐isocenter treat-
ment was well‐tolerated with all patients. The beam on time was
4.3 min and VMAT‐SBRT QA gamma passing rates were 98.1% (3%/
3 mm clinical gamma passing criteria), on average, demonstrating an
excellent potential for a fast, reliable, and accurate delivery of single‐
isocenter VMAT lung SBRT treatment for two lung lesions.
The single‐isocenter plan for treating multiple lung tumors has
been reported by a few investigators.29,30 For instance, using both
coplanar and noncoplanar nine fields IMRT (in Pinnacle TPS), Zhang
et al.29 compared those IMRT plans with helical Tomotherapy for sin-
gle‐isocenter/multitarget lung SBRT treatment. The prescription was
60 Gy in three fractions. In their study, it was concluded that com-
pared to IMRT, helical Tomotherapy gave better target coverage at
the cost of overall 73.0 ± 20.6 min treatment time. However, IMRT
treatment time was not reported. It was also highlighted that
compared to IMRT plans, Tomotherapy plan also gave a relatively
higher normal lung V5. Another study by Li et al.30 reported that they
treated two patients with single‐isocenter lung SBRT plan for more
than five lung metastases lesions. Their prescription doses were
48 Gy/8 fractions for Patient A (5 tumors) and 42 Gy/7 fractions for
patient B (7 tumors). Plans were generated in Monaco TPS (CMS
Software Inc., St Louis, MO) using a few partial‐arcs and delivered
with Elekta Axesse linear accelerator with 6 MV beam (660 MU/min).
The beam on time for each treatment was about 10 min. Both
patients were followed up, and the treatment was well‐tolerated by
the patients with a minimal toxicity. In contrast, utilizing 6 MV‐FFF
beam (in Eclipse) for Truebeam Linac our single‐isocenter VMAT plan-
ning technique delivered fast (average beam on time 4.3 min) and
effective treatment (curative high biological effective dose of >100–
150 Gy for each lesion) for relatively large cohorts of patients.
One potential concern for single‐isocenter VMAT‐SBRT plan for
two lung lesions was low dose spill in the normal lung, such as V20,
V10, and V5. Per RTOG recommendation, all our single‐isocenter/
two‐lesions VMAT lung SBRT plans had V20 < 10–15%. Moreover,
normal lung V5 was maintained less than 40%, on average.31–33
Although, in our experience when the isocenter to tumors distance
increased, the normal lung V10 and V5 slightly increased, as
expected, when compared to two‐isocenter plan. Our treatment
planning strategy favored minimizing normal lung dose during single‐
isocenter VMAT planning (by optimizing patient specific collimator
angles in conjunction with jaws tracking such that the leakage dose
due to the leaves travelling in between two tumors could be mini-
mized) that could potentially help reduce severe lung toxicity with
careful attention to V5 and V10 during plan optimization.
TAB L E 4 The detailed information on total number of MUs and beam‐on time for the both single‐isocenter and two‐isocenter plans for all
eight lung SBRT patients. The Octavius VMAT‐SBRT QA pass rates and point dose measurements for single‐isocenter plans were also shown.
Patient no. Plan type Total no. of MUs Beam‐on time (min) Gamma pass rates 3%/3mm (%) Point dose % diff. (%)
1 Two‐isocenter 10,069 7.19 — —
Single‐isocenter 5777 4.13 99.3 0.9
2 Two‐isocenter 13,198 9.43 — —
Single‐isocenter 10,727 7.66 91.7 1.8
3 Two‐isocenter 9095 6.50 — —
Single‐isocenter 6607 4.72 100.0 1.5
4 Two‐isocenter 7185 5.13 — —
Single‐isocenter 6029 4.31 100.0 2.3
5 Two‐isocenter 6219 4.44 — —
Single‐isocenter 4093 2.92 99.4 0.3
6 Two‐isocenter 9047 6.46 — —
Single‐isocenter 5047 3.61 94.3 0.4
7 Two‐isocenter 5608 4.01 — —
Single‐isocenter 4149 2.96 100.0 0.4
8 Two‐isocenter 10,500 7.50 — —
Single‐isocenter 5680 4.06 100.0 0.7
Mean ± SD Two‐isocenter 8865 ± 2330 6.3 ± 1.7 — —
Single‐isocenter 6014 ± 1963 4.3 ± 1.4 98.1 ± 3.0 1.04 ± 0.7
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Another potential concern for single‐isocenter VMAT plan was the
patient setup errors, for example tumor motion and rotational errors.
This may result in geographic miss and compromise the local tumor
control rates due to deformation. For single‐isocenter/two lesions
VMAT plan isocenter was generally chosen at the midpoint of the two
lesions, therefore, the isocenter distance between two lesions was
evenly distributed. However, it would be difficult to find a perfect mid-
point for noncoplanar lesions. The variability in respiratory patterns
between the CT simulation and the time of treatment was studied by
many researchers.34–37 It has been reported in the literature that there
were only small changes (within ±3 mm) due to intrafractional and
interfractional motion while using conventional multi‐isocenter lung
SBRT treatment. Their mean patient setup time from tumor localiza-
tion to the end of treatment CBCT scan was about 40 min.36,37 It was
recommended that a 5 mm PTV margin was sufficient to address
those motion errors. Furthermore, the spatial uncertainties for this
kind of beam arrangement were discussed by Dr. Gary A Ezzell for sin-
gle‐isocenter/multitarget cranial radiosurgery.38 In his paper it has
been demonstrated that for Truebeam CBCT the maximum spatial
uncertainties were less than 1.5 mm at 10 cm distance from the
isocenter tested using 12 targets bearing balls (BBs) phantom. Before
delivering each SBRT treatment, a daily quality assurance check on
kilovoltage to megavoltage imaging isocenter coincidence was per-
formed, including IsoCalc test for precise and accurate target localiza-
tion. Our IsoCalc localization accuracy for Truebeam was <0.5 mm at
isocenter. In addition, our off‐axis localization accuracy was similar to
that of previously reported values by Dr. Ezzell while measured using
an IsoCalc QA phantom embedded with the multiple BBs. All the qual-
ity assurance procedures were in compliance for SBRT treatment
delivery. Our image guidance CBCT matching parameters (at True-
beam) were consistent with those previous finding.
For our single‐isocenter/two‐lesion lung SBRT treatment, in addi-
tion to abdominal compression, the synchronous tumor motion was
captured at the 4D CT simulation and appropriate PTV margins were
applied for each tumor using MIP images. Using single‐isocenter plan
we have treated the PTV volume ranged from 5 to 90 cc (see
Table 1). With this treatment technique, our clinical experience was
that treating small tumors off axis would need an additional margin
to minimize residual spatial uncertainties as mentioned above. On
the other hand, treating larger tumors off axis may potentially spill
low/intermediate dose to the normal lungs due to the MLC transmis-
sion. Our treating physicians are aware of these dosimetric charac-
teristics and those residual spatial uncertainties were accounted
during target delineation. However, our average beam on time of
about 4.3 min per treatment could potentially decrease the possibil-
ity of changes on breathing signals from coughing or pain and mak-
ing geographic miss unlikely‐potentially improving patient stability.
In addition, due to rotational errors, for small targets and those
away from the single‐isocenter could potentially alter the dose distri-
butions. For those highly conformal VMAT plans, the small deviation
in motion error could potentially irradiate normal tissues, and it may
increase the chance of radiation‐induced toxicity or miss the target.
Our attending physician has addressed that issue by individually
reviewing these target volumes and the associated tumor motion
pattern and by assigning appropriate ITV to PTV margins (usually
5 mm in the medio‐lateral and anterior–posterior directions and 8 to
10 mm in superior–inferior direction) to accommodate potential
tumor deformation. Moreover, great care has been taken by our
treating physician and the physicist to address some of the above‐
mentioned issues, for example, being available for the patient setup
(in the 3D, 4D CT simulation and each treatment), image guidance,
and CBCT matching and physically authorizing each treatment frac-
tion for all patients. However, it is worthwhile to mention here that
the 8–10 mm superior–inferior expansion of the ITV to PTV is not a
requirement for an effective treatment of two lung lesions using a
single‐isocenter plan, but this was really only a conservative prefer-
ence of our treating physicians from their many years of lung SBRT
experiences. Further studies are required to validate the standard
5 mm ITV to PTV expansions that would be adequate or not for this
kind of treatment setting while fulfilling the RTOG compliance.
In summary, each plan was rigorously evaluated using the dosi-
metric parameters listed in the Tables 1, 2, and 3. All parameters
were deemed acceptable for both single‐isocenter and two‐isocenter
plans per SBRT protocol ‐ suggesting that single‐isocenter plan could
be dosimetrically equivalent to two‐isocenter plan and a faster and
equally effective treatment delivery which can be offered to well sui-
ted patients. In the future, these patients will be followed up clini-
cally and evaluated for local control rates and treatment related
toxicity such as the effect of normal lung dose as a function of
isocenter to tumors distance. Moreover, single‐isocenter VMAT plan
for SBRT of lung for more than two lesions will be investigated.
5 | CONCLUSION
This report presents our initial clinical experience with a single‐iso-
center for two‐lesion SBRT procedure for lung tumors and compared
with conventional two‐isocenter plan. Treatment of peripherally
located two lung lesions with centrally assigned single‐isocenter was
dosimetrically equivalent to two‐isocenter plan. For single‐isocenter
plans, it was observed that as the distance between the lesions
increased the normal lung V5, V10 and MLD somewhat increased.
The single‐isocenter technique was fast, accurate, and very well‐tol-
erated by all the patients, improving patient comfort and potentially
reducing the amount of intrafraction motion errors for well‐suited
patients. Clinical follow‐up of these patients is warranted to deter-
mine the tumor local control rates and treatment related toxicity.
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